SEB Concept Biotechnology Fund D
Equity fund
1 year
USA
Largest region
High
Risk
Annual costs
Morningstar
Partial
Sustainability
Development
Last 5 years
( ann.)
Description
- Fondet plasserer over hele verden i aksjer og aksjerelaterte verdipapir i bioteknologisektoren. Investeringene gjøres i selskaper som fokuserer på forskning, utvikling samt produksjon og distribusjon av bioteknologi og medisiner.
Investment horizon
- SEB Concept Biotechnology Fund D is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.
Characteristics
- Minimum amount
- Sharpe 3 years
- Price/NAV
27 Aug 2025
- Start date15 Oct 2000
- ISINLU0118405827
Risk
- High (5 of 7)
Morningstar rating
- The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.
Sustainability
- SustainabilityPartial
Costs
- Ongoing costs
Includes management fees of 1,50 %
- Platform fee
- Kickback fee
- Annual running costs
- Performance-based fee
Any transaction costs to the manager are not included in the cost overview. These are stated under cost details on the summary page before you purchase the fund. Costs for any currency exchanges are not included.
Allocation
- Stocks 99%Interest 1%
Portfolio
Shows the fund's largest investments.
- Gilead Sciences Inc8.9%
- Amgen Inc8.7%
- Vertex Pharmaceuticals Inc8.0%
- Alnylam Pharmaceuticals Inc6.7%
- Verona Pharma PLC ADR4.9%
- Regeneron Pharmaceuticals Inc4.8%
- AstraZeneca PLC ADR4.6%
- argenx SE ADR2.9%
- BioNTech SE ADR2.4%
- Insmed Inc2.3%